Sensorion Announces the Appointment of Peter Weber, MD, MBA, as Chief Medical Officer
Dr. Weber, an otologist and neurotologist who led the clinical development of the first FDA-approved gene therapy for genetic hearing loss, joins as SENS-601 advances into the clinic
MONTPELLIER, France & CAMBRIDGE, Mass., October 19, 2026--Regulatory News:
Sensorion (FR001401A9Z0 – ALSEN) ("the Company"), a pioneering clinical-stage biotechnology company that develops novel therapies to restore hearing and to treat and prevent hearing loss disorders, today announced the appointment of Peter Weber, MD, MBA, as Chief Medical Officer, effective November 2, 2026.
Dr. Weber is an otologist and neurotologist with more than two decades of clinical and industry leadership in hearing loss. Dr. Weber possesses deep expertise in rare genetic ear disorders and is one of the few physicians to have led the clinical development of gene therapies for genetic hearing loss.
Earlier, as Chief Medical Officer of Decibel Therapeutics, and later as Senior Medical Consultant to Regeneron, Dr. Weber guided several monogenic gene therapy programs for the inner ear. These included the otoferlin gene therapy that became the first FDA-approved gene therapy for genetic hearing loss. At Decibel, he also led a small molecule program to prevent hearing loss caused by cisplatin chemotherapy.
Most recently, Dr. Weber was Chief Medical Officer of Auregen BioTherapeutics. There he led a Phase I/II trial under an FDA-cleared IND of an autologous, 3D-printed cartilage implant to repair microtia in children, and the regulatory strategy that secured Orphan Drug Designation and Breakthrough Designation.
His other industry leadership roles include Chief Medical Officer of Frequency Therapeutics, where he led the IND and Phase I studies of a small molecule program to regenerate cochlear hair cells. He was also Global Chief Medical Officer and Vice President of Reimbursement at Cochlear Limited, where he led several successful PMA and 510(k) submissions worldwide.
Alongside his industry experience, Dr. Weber is Professor and Head of Otology, Neurotology and Skull Base Surgery at Boston University Medical Center, having previously held professorships at Mount Sinai Health System, the University of Massachusetts Medical Center, the Cleveland Clinic and the Medical University of South Carolina. He is board certified in Otolaryngology - Head and Neck Surgery and in Neurotology, has served as Editor-in-Chief of the American Journal of Otolaryngology since 2002, and has authored more than 125 publications and three books. Dr. Weber holds an MD from Albany Medical College, an MBA from Duke University, and a BS/MS in chemical and biomedical engineering from Washington University in St. Louis.